• NOVOb
• NVO

Novo Nordisk placed on JPM's Catalyst Watch list into headline data

• NVO

US minority veterans face unequal access to Ozempic and Wegovy, study finds

A study reveals racial inequities in the prescription of semaglutide for diabetes and weight loss in U.S. military veterans, particularly affecting Black, Asian, and Native American patients.

• NVO

Earnings call: Novo Nordisk sees robust sales growth in Q3 2024

• NVO

Novo Nordisk CFO says 2025 sales could see high-teens percentage growth

Novo Nordisk projects high teens sales growth for next year, following a 36% increase in 2023, with shares declining slightly post-analysis call.

• C
• COIN
• FSLR
• NVO
• RIVN
• SMCI
• TSLA
• WFC

Trump Media, Tesla, Citigroup rise premarket; Super Micro falls

Following Trump's presidential win, US stock futures surged, with notable rises in Trump Media, Tesla, and banking stocks, while some renewable and EV stocks declined.

• NVO

Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO

Novo Nordisk is increasing the supply of its weight-loss drug Wegovy in the U.S. and lifting prescription limits due to prior supply issues, as stated by the CEO.

• BMWG
• NVO
• SIEGn
• STOXX
• US500

European shares advance as Trump elected US president

• NOVOb
• NVO

Novo Nordisk reports 24% sales jump, driven by diabetes and obesity treatments

Novo Nordisk reported a 23% sales increase in 2024, driven by diabetes and obesity treatments, particularly Wegovy, with strong operational profits and ongoing R&D trials.

• NVO

Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast

Novo Nordisk reports strong Wegovy sales, beating analyst expectations despite overall sales falling slightly short, while navigating increased competition in the obesity drug market.

• CTLT
• LLY
• NVO

Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings

Catalent reports a surprising first-quarter loss amid Novo Holdings acquisition plans, with revenue falling short of expectations, raising antitrust concerns over competition in the weight-loss drug market.